Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Virulizin phase III trial extended to Canada and Mexico

April 23, 2003

Revimid granted fast track status for myelodysplastic syndromes

April 17, 2003

Canvaxin partial hold lifted, phase III enrollment to resume

April 17, 2003

Patient enrollment completed in phase IIa trial of Onyvax-P

April 17, 2003

AG-858/Gleevec combination therapy subject of new phase II trial in CML

April 15, 2003

Pharmexa seeks approval in Europe for phase II HER-2 DNA AutoVac trial

April 10, 2003

HYB-2055 enters the clinic

April 7, 2003

New patent broadens protection for Virulizin

April 7, 2003

Oxford BioMedica cleared to begin phase II trial of TroVax in colorectal cancer

April 3, 2003

Initiation of first of two expanded phase II trials of GVAX lung cancer vaccine

April 3, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...